# A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

> **NCT06044337** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Biogen** · enrollment: 322 (estimated)

## Conditions studied

- Subacute Cutaneous Lupus Erythematosus
- Chronic Cutaneous Lupus Erythematosus

## Interventions

- **DRUG:** BIIB059 (litifilimab)

## Key facts

- **NCT ID:** NCT06044337
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-10-03
- **Primary completion:** 2029-06-26
- **Final completion:** 2029-12-11
- **Target enrollment:** 322 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06044337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06044337, "A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06044337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*